Log In
Print this Print this

tobramycin inhalation solution (TOBI)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionInhaled tobramycin solution
Molecular Target Ribosomal 30S subunit
Mechanism of ActionProkaryotic protein synthesis inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationCystic fibrosis (CF)
Indication DetailsManage cystic fibrosis (CF) with P. aeruginosa; Treat cystic fibrosis (CF); Treat cystic fibrosis (CF) patients with mild lung disease
Regulatory Designation Australia - Orphan Drug (Manage cystic fibrosis (CF) with P. aeruginosa)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today